Analysis of Clinical and Investigatory Profile in the management and Outcome of Guillain – Barre Syndrome. by Ganesa Pandian, D
ANALYSIS OF CLINICAL AND INVESTIGATORY 
PROFILE IN THE MANAGEMENT AND OUTCOME 
OF GUILLAIN – BARRE SYNDROME 
 
 
Dissertation submitted to 
THE TAMILNADU DR.MGR MEDICAL UNIVERSITY 
 
In partial fulfillment of the requirements 
For the award of degree of 
 
DM (NEUROLOGY) – BRANCH-1 
 
 
 
MADRAS MEDICAL COLLEGE 
THE TAMILNADU Dr.M.G.R.MEDICAL UNIVERSITY 
CHENNAI. 
 
 
AUGUST 2014 
 CERTIFICATE 
 
 This is to certify that the dissertation entitled “ANALYSIS OF 
CLINICAL AND INVESTIGATORY PROFILE IN THE 
MANAGEMENT AND OUTCOME OF GUILLAIN – BARRE 
SYNDROME” is a bonafide record of work done by Dr. GANESA 
PANDIAN .D in the  Institute  of  Neurology,  Rajiv  Gandhi Government 
General Hospital & MADRAS MEDICAL COLLEGE, CHENNAI in partial 
fulfillment of the Tamilnadu Dr.MGR Medical University rules and 
regulations for the award of D.M. (NEUROLOGY) degree under my direct 
guidance and supervision during the academic year 2011-2014. 
  
  
  
Prof. Dr. S. BALASUBRAMANIAN, M.D., D.M., 
Professor of Neurology, 
Institute of Neurology, 
Madras Medical College, 
Chennai-3 
  
 
 
 
  
Prof. Dr. K. MAHESHWAR, M.S, M.Ch., 
Professor and Head of the Department, 
Institute of Neurology, 
Madras Medical College, 
Chennai-3 
Prof. Dr.R.VIMALA, M.D 
The Dean, 
Madras Medical College, 
Chennai-3. 
 DECLARATION 
 
I solemnly declare that this dissertation titled “ANALYSIS OF 
CLINICAL AND INVESTIGATORY PROFILE IN THE 
MANAGEMENT AND OUTCOME OF GUILLAIN – BARRE 
SYNDROME” is done by me in the Institute of Neurology, Madras Medical 
College & Rajiv Gandhi Government General Hospital, Chennai under the 
guidance and supervision of Prof. Dr. S. BALASUBRAMANIAN, M.D., 
D.M., Professor of Neurology, Institute of Neurology, Madras Medical 
College & Rajiv Gandhi Government General Hospital, Chennai. This 
dissertation is submitted to the Tamil Nadu Dr.MGR Medical University, 
Chennai in partial fulfillment of the university requirements for the award of 
the degree of D.M. Neurology. 
  
  
 
  
Place : Chennai 
Date  :                                            
Dr. GANESA PANDIAN .D 
Student, 
Institute of  Neurology,  
Madras Medical College,  
Chennai-3.       
  
ACKNOWLEDGEMENT 
 
 I am grateful to Dr.R.VIMALA,MD., Dean, Rajiv Gandhi Government General 
hospital, Madras Medical College, Chennai, for permitting me to utilize the hospital 
facilities in conducting this study. 
 I owe my gratitude to Prof.Dr.K.MAHESHWAR,MS.,Mch.,Professor of Neuro 
surgery, Head of the Department, Institute of neurology, Rajiv Gandhi Government General 
hospital, Madras Medical College who arranged the necessary facilities to carry out this 
study and guidance to complete the study. 
 I am deeply indebted to respected and beloved chief  
Prof. Dr.S. BALASUBRAMANIAN, M.D., DM., Professor of Neurology for her kind and 
able guidance, inspiration, constant support and encouragement throughout the period of the 
study. 
 I express my sincere thanks and gratitude to our Professors, Prof. Dr. K. Bhanu, 
Dip. NB., DM., Prof. Dr. G. Sarala, MD., DM., Prof. Dr. R. Lakshmi Narasimhan, 
MD., DM., DNB., and Prof. Dr. V.Kamaraj, MD., DM., for their valuable suggestions 
and support.  
 I am thankful to all my Assistant Professors for their valuable  guidance, timely 
advice and support. 
 I wish to express my sincere thanks to all the patients who willingly co-operated 
with me during the course of this study. 
 Above all, I thank the Almighty Lord God for enabling me to complete this study. 
  
 CONTENTS 
 
 
S.No. Topic Page No. 
1. Introduction 1 
2. Aim of the Study 2 
3. Review of the Literature 3 
4. Materials and Methods 35 
5. Results & Observations 38 
6. Discussion 58 
7. Conclusion 67 
 
8. Annexures  
 
 
• Statistical Method Applied 
• Bibliography 
• Proforma 
• Master Chart 
• Ethical Committee Approval Letter 
• Plagiarism Result 
 
 
 
1 
 
INTRODUCTION 
 
 Guillain-Barre Syndrome (GBS) or Acute Inflammatory  Demyelinating 
Polyradiculoneuropathy  is an acute onset, immune-mediated demyelinating 
disorder of the peripheral nervous system. The aetiology is thought to be 
widespread demyelination of the spinal roots and the peripheral nerves  due to 
a cross reaction between target antigen and myelin, axon or both.  Typical 
clinical features of GBS are progressive, symmetric muscle weakness 
associated with absent or depressed deep tendon reflexes. The disorder is 
heterogeneous and diverse in its antecedent events, clinical presentations and 
natural course. Although GBS often has a benign prognosis, 7% of patients die 
and further 16% suffer from residual disability. The modalities of treatment of 
GBS are  supportive treatment, ventilator management,  plasma exchange and 
immunoglobulins. 
 
 This study was undertaken to study the clinical and investigatory profile 
of Guillain Barre Syndrome in Rajiv Gandhi Govt. General  hospital, Chennai-
3  and in an to attempt to correlate certain clinical and electrophysiological 
features with prognosis, to identify a poor outcome group in the early stages 
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AIMS  & OBJECTIVES 
 
1.  To analyse the clinical profile of GBS                                                                                       
2. To study the prognosis in GBS with reference to:                                                                   
 a)  Age. 
 b)  Time taken to develop peak deficit from onset (in days). 
 c)  Duration of plateau phase. 
 d)  Time taken to onset of improvement. 
 e)  Requirement of ventilatory support 
 f)  Cerebrospinal fluid  analysis 
 g) Nerve  conduction study 
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REVIEW OF LITERATURE 
                                                                 
DEFINITION: 
 Guillain Barre Syndrome (GBS) is a relatively symmetrical, 
predominantly motor neuropathy, frequently involving facial and other cranial 
motor nerves with partial or total are flexia for which no specific cause can be 
demonstrated, although it is commonly preceded by a viral infection. It reaches 
a peak of disability within four weeks and follows a monophasic course with 
recovery.                                           
 
HISTORICAL BACKGROUND                                                                                                        
 Octave Landry is credited with the earliest description of what is now 
recognized as GBS. In 1859 he described a condition called 'acute ascending 
paralysis'. Eichorst in 1877 and Leyden in 1880 described the lymphocytic 
inflammation of nerve in some cases of peripheral neuropathy. 
 
 In 1916,  Guillain, Barre, and Strohl - French army neurologists, 
reported on two soldiers who developed an acute paralysis associated with the 
loss of muscle- stretch reflexes. They also described an elevation of CSF 
protein with a normal cell count (albuminiocytological dissociation). Andre 
Strohl was responsible for the electrophysiological aspects. In 1949, Haymaker 
and Kernohan described the clinical and histopathological features, including 
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inflammatory changes of the peripheral nerve in 50 fatal cases of GBS. In  the 
mid-1950s, Waksman and Adams produced experimental allergic neuritis in 
animals by injection of homologous or heterologus peripheral nerve tissue 
combined with Freund adjuvant. 
 
 Landry's paralysis and Guillain Barre Syndrome were thought to be 
different entities (with a benign prognosis for GBS and an ominous prognosis 
for Landry's paralysis) till Haymaker and Kernohan in 1949, exhaustively 
reviewed this debate and entitled their paper Landry-Guillain-Barre syndrome 
implying that the two condition are identical 
 
 C. Miller Fisher in 1956 observed a variant associated with 
ophthalmoplegia, ataxiaand areflexia.  In the 1980s, plama exchange was 
found to be an effective treatment,  and in  the 1990s, efficacy was also 
demonstrated for intravenous immunoglobulins                                                                       
 
PATHOLOGY:                                                                                                                 
 GBS is increasingly recognized to encompass several 
pathophysiological patterns. However the most prevalent form of GBS in most 
of the world is acute inflammatory demyelinating polyneuropathy (AIDP). 
This form is characterized pathologically by demyelination and macrophage 
mediated clearance of myelin. Classically, a perivascular mononuclear 
inflammatory infiltrate of lymphocytes, monocytes and plasma cells is seen in 
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endoneurium and myelin sheath. Patchy, segmental, multifocal demyelination 
is present along peripheral nerves, including nerve roots, whereas the axons 
themselves are relatively spared except in the more severe cases. This 
abnormality is prominent around ventral roots and in the plexus and proximal 
nerve trunks, but may, in some are associated with a higher incidence of 
antibodies to ganglioside GM-1 and Campylobacter infection. 
 
PATHOGENESIS :                                                                                                            
 The pathogenesis of GBS remains incompletely understood, but it is an 
autoimmune disorder that can often be linked to an antecedent infection. The 
autoimmune hypothesis of GBS is based largely on the close correlation 
between GBS and experimental allergic neuritis (EAN), and the failure to 
associate any single infectious agent with the diseases. Also, failure to 
associate autoimmune response to any defined peripheral myelin autoantigen, 
raises the possibility that a number of autoantigens may be involved.  
 
 EAN, induced by immunizing rabbits or guinea pigs with peripheral 
nerve is produced by inoculation with myelin and a species-specific antigen or 
its fragments. The experimental disease appears to be predominantly cell 
mediated.            
 
 Thus, current work supports the concept of a primary lymphocytic cell 
mediated mechanism for inflammation in GBS, presumably as an aberrant 
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response to a precipitating infection or other immunological stimulus. 
Activated T- cells expressing several surface receptors circulate during the 
active illness and serum levels of interleukin-2 and its soluble receptor are 
greatly increased. Some T-cells are  sensitized to P-2, a major peripheral nerve 
myelin antigen, but specificity of this response is unclear. 
 
 Humoral  factors including both antibodies and complement may also 
play a role in GBS as evidenced by efficacy of plasmapheresis in the 
complement activation products C3a and C5a in the CSF, soluble C5b-9 
complexes in serum and CSF, and deposits of complement and IgM on myelin 
sheaths in biopsy specimens from patients with GBS. 
 
 Circulating antineural antibodies against a number of antigens have been 
demonstrated in GBS including against P-2 protein of nerve myelin and a 
variety of glycoconjugates like GM-1, GD 1b, asialo -GM1, SGPG and 
sulfatide. 
 
 A causal link between a preceding infection and GBS has been 
constructed based on concept of molecular mimicry. An autoimmune response 
initially launched against the invading organism would secondarily produce 
damage to peripheral   nerve.                                                                                                            
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Fig. 1 : Diagrammatic representation of probable cellular  
events during GB5. 
 
 
 A) Lymphocytes attach to the walls of endoneural vessels and migrate 
through the vessel wall, enlarging and transforming as they go. At this point, 
no nerve damage has occurred; myelin and axons are intact. 
 
 B) More lymphocytes have migrated from the vessel lumen into the 
surrounding tissue, and macrophages have made their appearance. The first 
visible morphologic effect is segmental demyelination i.e., breakdown of 
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myelin with sparing of the axon. Segmental demyelination is by far the most 
common structural change in nerve fibres in GBS. 
 
 C) The lesion is more intense, and, as a result, there is interruption of the 
axon in addition to myelin sheath damage. Polymorphonuclear leukocytes are 
present as well as lymphocytes and macrophages. Because the axon is 
interrupted, the muscle undergoes denervation atrophy, and the nerve cell body 
shows the changes of central chromatolysis. 
 
 D) If axonal damage has occurred proximally because of a particularly 
intense root or proximal nerve lesion, the nerve cell body may die and undergo 
dissolution. In this situation, there is no hope of regeneration, although there is 
presumably the possibility of collateral reinnervation of muscle from surviving 
motor fibers.          
 
ANTECEDENT EVENTS : 
 A variety of antecedent events have been noted to precede onset of 
GBS. In one study of Ropper et al at Massachusetts General Hospital, 27% had 
no prior identifiable illness or antecedent event, 49% had an upper respiratory 
infection, 10% had a diarrhoeal  illness, 3% had some form of pneumonia, 3% 
had  Epstein-Barr virus, 3 % had cytomegalovirus infection, 3% general 
malaise noted and 3% had miscellaneous events including Hodgkin's disease, 
surgery, systemic lupus, or vaccination. 
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 Approximately two thirds of cases of GBS follow an infection, usually 
viral including HIV, Cytomegalovirus or Epstein Barr virus with hepatitis or 
mononucleosis. Asymptomatic hepatitis, presumably viral, has also been seen. 
GBS has been reported to follow all the common childhood viral diseases, 
including measles, chicken pox, rubella, mumps and influenza A and B 
infections.  Campylobacter jejuni enteritis has been recently recognized as an 
important preliminary illness, often associated with severe or variant forms of 
neuropathy. 
 
 Vaccination of various types, general surgery, epidural anaesthesia, and 
drugs, including thrombolytic agents and heroin have been associated with a 
few cases. After much debate, the incidence has favoured a slight increase in 
cases of GBS attributable to the inoculation programme for swine influenza in 
1976. GBS is an occasional complication of rabies vaccination 16, especially 
with neural tissue containing vaccines. The median time from the first 
injection to onset of neuropathic symptoms is 11 - 15 days. Those cases with 
the shortest incubation period tend to be the most severe. Only a few cases of 
the syndrome have been reported following duck embryo rabies vaccine or 
human diploid cell rabies vaccine. An association with typhoid vaccine and 
tetanus toxoid is possible. However association with other vaccines remains 
doubtful at present. 
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 A small category of GBS occurs in the presence of an underlying 
systemic disease, most commonly systemic lupus erythematosus (SLE), 
Hodgkin's disease (and less frequently other neoplasia), Sarcoidosis or recently 
acquired HIV infection. These occur more frequently in patients with chronic 
inflammatory demyelinating polyneuropathy, perhaps because the immune 
dysfunction is also chronic, rather than monophasic, as in the infections that 
precede acute GBS. Autoimmune diseases other than SLE are only rarely 
associated with a demyelinating polyneuropathy but they can cause multiple 
vasculitic mononeuropathy,  immunocompromised patients may acquire GBS, 
even while they are taking high dose corticosteroids. Lyme disease is not 
typically associated with GBS, but it causes a similar subacute neuropathy 
 
CLINICAL FEATURES :                                                                                                          
 Usually, patients experience an acute respiratory or gastrointestinal 
illness that lasts for days and then resolves. This is followed in 1 to 2 weeks by 
the development of an 'ascending' paralysis. Typically, GBS begins with fine 
paresthesiae in the toes or fingertips, followed within days by motor weakness 
 
Weakness: 
 Typically the legs are involved initially, and within a few days, the 
arms. Patients will complain of difficulty in walking, trouble in arising from a 
chair, going up or down stairs, or instability of gait. Limb weakness is 
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relatively symmetric, and there is symmetric loss of the muscle stretch 
reflexes. Variable arm, facial and oropharyngeal weakness follows. 
 
 Weakness tends to progress, usually over a course of 1 to 3 weeks. 50% 
patients reach maximal weakness by 1 week, 70% by 2 weeks, and 80% by 3 
weeks. Occasionally, fulminant rapidly progressive course occurs, in which 
paralysis becomes maximal within 1 or 2 days. 
 
 In severe cases the disease may progress to affect respiration, eye 
movements, deglutition, and  autonomic functions. About one third of patients 
develop involvement requiring mechanical ventilation. 50% develop cranial 
nerve involvement, which is most often facial weakness. One half of patients 
develop oropharyngeal weakness. And 10% to 20% develop significant 
autonomic dysfunction (including fluctuations of blood pressure, heart rate, 
ileus, or urinary retention).  
SENSORY                                                                                                                    
 Although symptoms are predominantly motor, sensory disturbances in 
the form of distal paresthesias and numbness are frequently described by the 
patient. Typically, GBS begins with fine paresthesiae in the toes or fingertips, 
followed within days by motor weakness. Pain is common, as either bilateral 
sciatica or aching pain, similar to the muscle discomfort following exercise, 
involving the large muscles of the thigh, flanks, or back. However objective 
sensory deficit is only rarely found. Some patients may have joint position and 
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vibratory sensation impairment, and stocking-glove deficits to pinprick are 
occasionally found. 
 
Autonomic dysfunction :                                                                                           
 Autonomic neuropathy is a common and important complication and 
may involve both sympathetic and parasympathetic fibers. While minor 
autonomic dysfunction probably occurs in a large percentage of cases, 
significant autonomic dysfunction occurs in 10% to 20% of patients. 
 
 Serious cardiovascular dysfunction may present as sustained or episodic 
hypertension, pronounced blood pressure fluctuations and orthostatic 
hypotension. The most common abnormality is sustained sinus tachycardia, 
which usually does not require treatment. Sinus arrhythmia may also be seen. 
Vagally mediated arrhythmias such as profound bradycardia and cardiac arrest 
are more ominous and may require atropine and cardiac pacemakers. 
 
 Autonomic neuropathy may also involve the sudomotor, gastro-
intestinal tract and other systems presenting as excess sweating, constipation 
or nausea (from reduced bowel motility), urinary retention and impotence. 
 
 After the progression of weakness stops, patients tend to plateau for 2 to 
4 weeks and then slowly recover. The typical patient becomes bedridden with 
distal paresthesias, incomplete bilateral weakness of facial muscles, some 
difficulty in swallowing, and a vital capacity that is about half of the predicted 
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value. In the mildest cases, the patient can still rise from a kneeling position 
and walk on the heels and and toes whereas in the worst cases the patient is 
quadriplegic and ophthalmoplegic and   requires mechanical ventilation. 
However, in most, the recovery is such that by 6 months into the course of 
illness, 85% of patients are ambulatory. 
 
 In 3% of cases there is recurrence of the paralytic illness, although some 
of these patients may have instead a chronic inflammatory neuropathy, as 
opposed to recurrent GBS.  
 
 Overall, the mortality from the acute illness is 2% to 5%. About one half 
of patients have some degree of long-term residual symptomatic abnormality. 
15% to 20% cases have residual motor weakness at 1 year, and 5% remain 
severely disabled. 
 
VARIANTS : 
 Of the many various from this typical clinical presentation, the 
commonest but most aberrant is Miller- Fisher's Syndrome which involves 
ophthalmoplegia, ataxia and areflexia with little weakness and accounts for 5% 
of cases in a large series. 
 
The other variants are : 
1. Acute sensory loss associated with areflexia and peripheral 
demyelination. It must be distinguished from acute sensory neuropathy. 
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2. Acute autonomic neuropathy (acute pandysautonomia) first described by 
Young and coworkers, may be a variant of GBS, affecting only the 
autonomic nervous system, but this still remains to be proven. 
3. Weakness without paraesthaesiae or sensory loss. 
4.  Isolated weakness of the arm and oropharynx or of the leg. 
5. Acute polyneuritis cranialis not involving the first or second cranial 
nerves, may be a variant of GBS, when there is a monophasic illness 
with acute onset, raised CSF protein and recovery and no other cause is 
found. 
6. Bilateral weakness of facial muscles with distal paraesthesia. 
7. Axonal GBS with rapid, almost complete paralysis and electrically 
inexcitable motor nerves. 
8. Pharyngeal cervical-Brachial weakness (resembling Botulism or 
Diphtheria). 
9. Paraperesis resembling a spinal cord lesion-areflexic paraperesis sparing 
power and reflexes in the arms, face, and respiratory muscles throughout 
the illness 
10. Severe ptosis without ophthalmoplegia - severe ptosis of the upper lids 
with minimal or no opthalmoplegia or iridoplegia, and mild facial 
weakness early in their illness, progressing to typical GBS of the 
restricted pharyngeal - cervical - brachial form. 
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11. Acute severe midline back pain -seen as the first symptom, on waking or 
beginning paroxysmally after rolling over in bed; the pain was described 
as excruciating, and was so distracting that the patient screamed 
repeatedly. The pain abated over two to three days, as a typical GBS 
including bifacial paresis, evolved. 
 
 All are linked to GBS by the regional or global decrease in tendon 
reflexes, transitional forms of the disease, shared electro-physiological features 
and elevated concentration of protein in cerebrospinal fluid. 
 
 In 1956, C. Miller Fisher reported "an easily recognizable syndrome 
characterized among other features by total external ophthalmoplegia, severe 
ataxia and loss of the tendon reflexes". This well recognized variant of GBS 
has given the eponym of Fisher's syndrome, and accounts for about 5% of the 
cases of acute GBS in most series. 
 
 Patients typically present with diplopia followed within several days by 
ataxia or clumsiness of the limbs. One half of patients describe paresthesias 
and some patients describe dizziness. Over the first week of neurological 
symptoms, patients usually develop hypoactive or absent muscle stretch 
reflexes. The ophthalmoplegia evolves over 1 to 3 days and is usually severe, 
complete and relatively symmetric. Most patients have ptosis. Pupillary 
function tends to be normal. Occasionally, other cranial nerves are involved, 
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resulting in oropharyngeal or facial weakness. About one third of the patients 
develop associated severe limb weakness with respiratory failure. 
 
 The presence of ataxia has raised the question of cerebellar involvement. 
 
 There may be intention tremor, suggesting a cerebellar deficit. Some 
have unsteadiness, lightheadedness, or dizziness. However, vertigo, 
nystagmus, cerebellar dysarthria, and scanning speech are usually absent. 
 
 Patients which Fisher's syndrome most often have an elevated spinal 
fluid protein, but they are more likely than typical GBS patients to have 
normal CSF. The electrophysiologic studies show mild slowing of nerve 
conduction velocities compared with typical GBS and are more likely to be 
normal in the limbs than  
 
INVESTIGATIONS :                                                                                                                 
CSF ANALYSIS:  
 Within first few days, most patients develop an abnormal spinal fluid 
profile,with high cerebrospinal fluid protein in the absence of a 
pleocytosis(albuminocytologic dissociation). Glucose is normal, as are 
cultures. The elevation of CSF protein is presumed to result from a breakdown 
of the blood-CSF barrier. In the first day or two, the CSF protein is commonly 
normal. In Popper's series, 34% of patients had normal CSF protein in the first 
week, whereas in the second week only 18% were normal. Serial CSF studies 
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may be needed to demonstrate an abnormality. Upto 5% to 10% of GBS 
patients may have a lymphocytic pleocytosis, with as many as 100 
WBC/cumm. In patients with CSF pleocytosis, a possibility of GBS associated 
with HIV infection, Lyme diseases, or sarcoidosis should be considered. 
 
 The examination of CSF typically shows normal pressure, few or no 
cells, and a protein concentration above 0.55g/litre after the first week of 
illness. A normal CSF protein level, particularly in the early illness, or a 
finding of numerous lymphocytes does not exclude the diagnosis, but a protein 
level above 2.5 mg/litre raises the suspicion of spinal cord compression and 
pleocytosis may signify Lyme disease, neoplasis, HIV, sarcoid meningitis or 
other disease. 
 
NERVE CONDUCTION STUDIES : 
 Abnormalities of nerve conduction are most sensitive and specific 
laboratory findings in GBS. They occur earlier and more frequently than 
elevation of protein in the CSF. 
 
 Electromyography and nerve conduction studies can document 
peripheral nueorpathy that is of a demyelinating type. The characteristic 
findings of presence of  early demylination i.e., conduction block. 
Demyelinating neuropathy tends to produce very slow nerve conduction 
velocities, dispersed compound muscle action potentials (CMAP), and 
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multifocal conduction block. Initially, the abnormality on nerve conduction 
studies may be limited to very prolonged F-waves. Conduction block in motor 
nerves causes the weakness in GBS, and spontaneous discharges in 
demyelinated sensory nerves probably cause the paresthesia and pain. 
 
 In the first few days the nerve conduction studies may be normal or only 
mildly abnormal. The electrophysiological abnormalities tend to lag behind the 
clinical examination. Severe reduction in the CMAP amplitudes may predict 
the long- term outcome. Miller et al showed that CMAP amplitudes less than 
10% of normal were associated with a less favorable long-term prognosis. 
Similarly, the North American Guillain-Barre study group noted a worse 
prognosis associated with CMAP amplitude less than 20% of normal. 
However such observations are not universally accepted as Triggs found that 
50% of patients with severely reduced CMAP amplitudes were clinically 
normal at 1 year. 
 
 Normal electrophysiological studies after several days of illness, 
particularly in patients with substantial weakness should direct attention away 
from GBS. 
 
 Alternative diagnosis are also suggested by reflexes that remain normal 
for more than several days in weak and paresthetic limbs, marked asymmetry 
in weakness, or fever in initial stages a few patients may have a band sensation 
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around the thorax, transient sensory levels, persistent but diminished reflexes, 
early urinary retention or Babinsky's signs without other signs of myelopathy, 
but presence of aberrant findings or diminished sensations below a trunk 
indicates spinal cord disease 
 
COMPLICATIONS :                                                                                                                   
 The common complications of GBS include respiratory failure, 
atelectasis, aspiration, pneumonia, bladder dysfunction, pain, depression, 
phlebitis, pulmonary embolus and syndrome of inappropriate antidiuretic 
hormone secretion (SIADH) exacerabated by positive pressure ventilation. 
Pseudotumor cerebri, papilloedema alone and unexplained seizures have been 
reported. 
 
 Further complications from immobility and bedrest include decubitus 
ulcers secondary compression neuropathy such as ulnar neuropathy and 
peroneal neuropathy, and the psychiatric sequelae associated with a prolonged, 
immobilizing stay in the ICU. 
 
DIAGNOSIS 
 Early acute GBS may be difficult to identify and has no pathogomonic 
features, but fully evolved pattern is easily recognised. 
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 In 1978, National Institute of Neurological and Communicative 
Disorders and Stroke (NINCDS, now NINDS) criteria for diagnosis of GBS 
were revised.  
 
Diagnostic Criteria for classical GBS                                                                                       
A. Features required for diagnosis : 
1. Progressive motor weakness of more than 1 limb.                                                        
2. Areflexia. 
 
B. Features strongly supporting the diagnosis :                                                                    
i. Clinical features:                                                                                                                          
1. Progression of symptoms and signs over days upto 4 weeks.                                        
2. Relative symmetry of symptoms. 
3. Mild sensory symptoms or signs.                                                                                       
4. Cranial nerve involvement, especially facial diplegia.                                                        
5. Recovery beginning 2-4 weeks after the progression ceases.                                              
6. Autonomic dysfunction.  
 
Absence of fever at the onset of illness.                                                                                 
ii. . CSF picture:                                                                                                                           
1. Elevated CSF protein after 1 week of symptoms. 
2. Cell counts of less than or equal to 10 mononuclear leucocytes per cumm of 
CSF. 
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iii. Electrodiagnostic studies:                                                                                                       
1. Evidence of nerve conduction slowing or block.                                                                             
 
C. Features making the diagnosis doubtful :                                                                        
i. Marked persistent asymmetry of weakness.                                                                   
ii. Marked bladder or bowel dysfunction at the onset or its persistence thereon.                                       
iii. Presence of polymorphonuclear leucocytes or > 50 mononuclear leucocytes 
per cumm of CSF. iv. Sharp sensory level.                                                                             
 
D. Features excluding the diagnosis.                                                                                      
1. Diagnosis of acute intermittent porphyria or recent diphtheria infection. 
2. Diagnosis of botulism, poliomyelitis, hysterical paralysis, toxic neuropathy 
(lead, nitrofurantoin dapsone) or history of hexacarbon abuse.  
 
3.Pure sensory syndrome                                                                                                                  
Suggestions and comments regarding modification of the above criteria were 
subsequently proposed by Asbury and Cornblath in 1990. These are as 
follows: 
 
1. Distal areflexia with definite hyporeflexia of biceps and knee jerks will 
suffice if other features are consistent. 
2. Fever may be present at the onset of symptoms.                                                                
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3. Severe sensory loss with pain can be seen in some cases. 
4. Occasionally the patient's disease will continue to progress for more than 4 
weeks 
5. Occasional patient may have severe ataxia, dysarthria, extensor plantar 
responses and ill-defined sensory levels. These need not exclude the diagnosis 
if other features are typical. 
6. Very rarely in CSF, proteins fail to rise in the 1 to 10 weeks period after 
onset of symptoms and mononuclear cell counts upto 50 per cumm may be 
seen. The lack of albuminocytological dissociation in some patients of GBS 
has also been reported from India. In HIV related GBS, the cell count of upto 
50 cells/cumm is considered a normal, rather than a variant. 
7. upto 20% of patients may have normal conduction studies, and more over 
these may not become abnormal until several weeks into the illness. The yield 
of findings consistent with demyelinating neuropathy is increased by studying 
late responses (F waves and H reflexes), evaluating proximal nerve segments 
nd performing precise enough measurements to determine whether partial 
conduction block and abnormal temporal dispersion exist. 
 
TREATMENT: 
 All patients with suspected GBS should be hospitalized for vigilant 
monitoring due to the high risk of respiratory failure and need for intubation 
and mechanical ventilation. Baseline spirometry, including FVC and oximetry, 
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should be obtained. The cornerstone of treatment is that of meticulous general 
medical support. 
 
 Very mild cases with only distal paresthesia and mild limb weakness 
may not need treatment, but it is advisable to wait approximately two weeks 
before concluding that there will be no further progression. Patients with vital 
capacities that are rapidly declining or below 18ml/kg or those with 
cardiovascular dysautonomia are appropriate candidates for observation in an 
ICU.    
 
 The most important advances in treatment of GBS have been positive 
pressure ventilation and intensive respiratory and medical management in the 
ICU, both introduced during the European Poliomyelitis Epidemic of the 
1950s. These have allowed patients with complications of immobilisation and 
respiratory failure to survive and recover from paralysis. 
 
The criteria advocated for intuabation, weaning and extubation in GBS are:               
A. Intubation : 
1. Mechanical ventilatory failure with vital capacity (VC) of 12-15 ml/kg. 
Falling VC over 4-6 hours or clinical signs of fatigue (brow sweating, 
tachycardia, hyperpnea) may prompt intubation at 15ml/kg                                                             
2. PaO2 less than 70mmHg on inspired air. 
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3. Severe oropharyngeal paresis with difficulty in clearing secretions or 
repeated coughing and aspiration  after swallowing.  
 
B. Weaning from ventilator: 
1. When VC exceeds 8-10 ml/kg with adequate oxygenation maintained with 
35- 40% inspired oxygen. 
2. Patient can voluntarily double resting minute volume.                                                  
 
C. Extubation : 
1. When continuous positive airway pressure of 5-7 cm of water was tolerated 
without clinical signs of fatigue for 12-24 hours                                                                           
2. Arterial Pao2 greater than 9O mmHg on room air.                                                          
3. Adequate alveolar ventilation.                                                                                            
4. Improvement in bulbar paresis. 
 
 Although many patients of GBS have clinical signs of fatigue of 
respiratory muscles, only 10% - 30% patients eventually require mechanical 
ventilation. Indications for intubation include an FVC dropping below 12ml/kg 
or in a normal- sized adult, FVC falling below 1 liter patients who are 
subjectively dyspneic or appear to be struggling to breathe should be intubated, 
even if their FVC is above these levels. In general one should err on the side of 
early intubation than late. A simple bedside estimate of FVC can be made by 
having the patient count out loud. If the patient can take a maximal inspiration 
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and then can count upto 25 probably about 2 liters. A patient who can count 
upto 10 probably has about 1 liter FVC. 
 
 In patients with respiratory failure, the average duration of machine 
assisted respiration has been 50 days. In a study form India, 30% of the 
patients studied required mechanical ventilation. 
 
 In patients with respiratory failure, the average duration of machine 
assisted respiration has been 50 days. In a study form India, 30% of the 
patients studied required mechanical ventilation. Weakness of facial, truncal, 
neck, bulbar and proximal weakness of upper limb and automic disturbances 
were predictors for need for subsequent mechanical ventilation. 
 
 The prevention of nosocomial infections is another central feature of 
treatment, since 25% of patients acquire pneumonias and 30% acquire urinary 
infections. Prophylaxis for pulmonary embolism, adequate nutrition, and 
psychological care are the other major areas of concern in severe cases. 
 
 As many as 30% of patients with GBS, experience significant pain early 
in their presentation and may be more pronounced in the limbs. Conventional 
analgesics may be useful, in addition to those commonly used for treating 
neurogenic pain (such as tricyclic antidepressent medications). Alternatively, a 
brief course of high-dose corticosteroids can lead to marked improvement in 
pain control. 
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IMMUNOTHERAPY OF GBS :                                                                                  
Corticosteroids : 
 For 50 years corticosteriods were the main stay of treatment for acute 
GBS on the basis of anecdotal experience, a few uncontrolled studies and the 
appeal of their anti-inflammatory effect. 
 
 Two randomized controlled trails, one using conventional doses of 
prednisolone for two weeks41 and the other, use high dose (500 mg) 
intravenous methylprednisolone42 daily for 5 days have found no benefit. 
Steroids are thus no  longer considered useful for GBS. 
 
Plasma Exchange: 
 Evidence of the presence of antibodies43 or demyelinating serum factors 
has provided a rationale for use of plasma exchange in therapy of GBS. In 
1978, Brettel et al44 first reported the benefits of plasma exchange in the 
treatment of GBS. Since then, several trials have been confirmatory.                                        
 
 Three large studies-North American GBS study group,45 the French46 
and Swedish13 trials have established benefits of plasma exchange. The 
conclusions derived from these three trials were: Plasma exchange is beneficial 
in acute GBS; It favourably modifies poor prognostic  factors; Maximum 
benefit is obtained when it is instuited early(within first 2 weeks)                                         
In the usual regimen of plamapheresis,21 a total of 200-250ml. / kg body 
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weight is removed in 4-6 cycles on alternate day The time required to 
complete a series of exchanges is 8 - 14 days. Plasma as replacement fluid is 
not recommended46 and now a days albumin or saline is used. The type of 
replacement fluid (albumin / saline) used in plasma exchange has not been 
found to influence the outcome. 
 
 Patients undergoing plasma exchange on continuous flow machine have 
a better outcome than on intermittent flow machines.33 Two continuous flow 
techniques can be used : Ultrafiltration and centrifugation. In a recent study, no 
difference was found.47 
 
 Indications for starting plasma exchange in patients of GBS have been 
advocated by Mckhann and Griffin.48 These are: inability to walk unaided; 
rapid and significant reduction in serial vital capacity and onset of bulbar 
paralysis. The benefit of plasma exchange is diminished if treatment is begun 
after two weeks of illness but some patients still seem to benefit if their 
condition continued to worsen during third week. After an initial good 
response with plasma exchange, some patients may show deterioration 
necessitating further series of plasma exchange. 
 
 Complications of plasma exchange49 also has certain practical 
limitations like: availability of technical set up and trained personnel to carry 
out the procedure; greater risk for patients with cardiovascular complications 
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or marked dysautonomia (associated with GBS) and small but real risk of 
transfer of infections (hepatitis and HIV) when plasma is used as replacement 
fluid. 
 
 Modified Plasma Exchange: A study from India50 showed that small 
volume plasma exchange (10 -15ml/kg of plasma exchanged on consecutive 
days) during first two weeks of the illness showed results comparable to that of 
conventional plasma exchange (200 -250 ml/kg). A similar study report from 
Sri Lanka61 has supported this fact. All this was achieved at a lower cost and 
fewer complications which is important for widespread application in 
developing countries. The replacement fluid used in these studies was fresh 
frozen plasma.  
 
Immunoglobulins:                                                                                                                 
 High dose intravenous immunoglobulin was first reported to be 
beneficial in GBS by Kleywey et al52 in 1988. 
 
 Intravenous immunoglobulin has been found to be useful in treatment of 
many diseases with an autoimmune basis. The proposed mechanisms53 for 
their action  
a. Passive transfer of neutralizing anti-idiotypic antibodies against auto 
antibodies. 
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b. Intravenous immunoglobulin alters the structure and dynamics of the 
idiotypic network in the auto immune patient to regain physiological control of 
auto immunity. 
 
 During the first week of illness, the preferred treatment for patients with 
GBS who have severe disease and require assistance to walk is either 
plasmapheresis or intravenous immunoglobulin. A controlled, randomized 
trial47 comparing intravenous immunoglobulin treatment with plasma 
exchange concluded that intravenous immunoglobulin was also effective as 
first line treatment. In this study, 52.7% of 74 patients receiving 
immunoglobulin compared with 34% of 73 patients undergoing plasma 
exchange had functional improvement of one grade or more after 4 weeks. 
Although immunoglobulin was clearly more efficacious, this findings was 
challenged because response to plasma exchange in this study47 was inferior to 
that in earlier studies.45 This prompted a new multinational, multicentre trial54 
that compared efficacy of immunoglobulin alone, plasmapheresis alone and 
plasmapheresis followed by immunoglobulin. After 4 weeks of treatment and 
48 weeks of follow up, no statistically significant difference was seen between 
the treatments. 
 
Consequently the question of which therapy is preferable for using first 
considering their similar efficacy and cost is a matter of convenience and 
practicality.55 
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 The indications for immunoglobulin in GBS have not been clearly laid 
down yet. In the Dutch study trial,47 inclusion criteria included acute GBS, 
inability to walk 10metres independently and presentation within 2 weeks of 
disease onset.  If the illness continues to worsen in the first 15 days despite a 
full course of plasma exchange, a trial of immunoglobulin therapy55 is 
warranted. The dose recommended is 0.4g/kg/day for 5 days.  Just like plasma 
exchange, the use of immunoglobulin has also been associated with treatment 
related fluctuations. 
 
 Adverse reactions55 to immunoglobulin therapy are usually minor and 
occur in about 10% of patients. Side effects include fever, myalgia, headache, 
meningism, and eczema on hands. There is also an increased risk of 
thromboembolic events, as therapy with immunoglobulin increases serum 
viscosity. Anaphylaxis is very rare but potentially fatal. Immunoglobulin 
should be used with extreme caution in patients with renal failure which it may 
exacerbate. 
 
REHABILITATION:                                                                                                    
 Rehabilitation requires an organised program with definite end points. 
There are no systematic studies of physiotherapy in GBS. But early goals 
include, preventions  of decubitus ulcers, tendon shortening, joint 
malalignment, peroneal nerve compression palsies and facilitation of 
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pulmonary toilet. Psychological problems in form of depression, mental 
fatigue, impotence and those due to residual weakness should also be tackled. 
                                                                                              
OUTCOME: 
 Although GBS is often thought to have a benign prognosis, 7% of 
patients die and a further 16% suffer significant residual disability.66 
 
 Speed of recovery varies and may take 6-8 months; no improvement is 
expected after 2 years.57 Remyelination is usually complete but recovery is 
poor when there has been Wallerian axonal degeneration58 after which the 
axons regrow at 1mm per day - so many do not reach their target muscles for 
several years if at all. 
 
 The death rate has varied from 1.3% in different series with a mean of 
6%, probably depending more on the quality of intensive care than specific 
treatments. Half of the deaths58 are within first month - one third from 
cardiovascular autonomic complications such as asystole; a quarter from 
pneumonia or respiratory failure and the rest from pulmonary embolism, 
infection, infarction, renal failure and unrelated cause. 
 
 With the currently available modalities of treatment, it is estimated that 
about 15% of GBS patients completely recover without any deficit and another 
65% have persistent minor problems that generally do not impair conduct of 
everyday life.21 The disease in itself does not result in chronic fatigue but mild 
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depression indicated by persistent mental fatigue is common. A few men have 
residual impotence. Three percent of patients may have one or more 
recurrence57 of the disease. 
 
PROGNOSIS                                                                                                              
 Although the majority of patients with GBS make an acceptable 
functional recovery,a proportion succumb to the acute illness while others 
retain significant residual disability. It is thus important to be able to select 
only patients with a poor prognosis for treatment, which often involves 
discomfort, expense and risk  others retain significant residual disability. It is 
thus important to be able to select only patients with a poor prognosis for 
treatment, which often involves discomfort, expense and risk of complications. 
 
 No large-scale prospective study has ever been carried out and the 
available retrospective studies give an incomplete picture of outcome. It is also 
difficult to estimate how many patients remain disabled from literature. Hence 
a number of small studies have been conducted to correlate particular clinical 
features with a poor outcome 
 
 Osier and Sidell59 suggested that patients with a strictly motor 
neuropathy and no sphincter disturbances were more likely to have a benign 
prognosis. However Marshall60 described 37 patients including some with 
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severe sensory loss or sphincter disturbance and could find no evidence that 
such features influenced outcome adversely. 
 
 A particularly severe motor deficit appears to carry a greater risk of 
residual disability according to a number of authors.61 Two paediatric studies 
61,62
 have suggested that the time taken to improve also has prognostic value. 
They concluded that an interval of greater than 18 days from maximum deficit 
to onset of improvement (plateau) was associated with incomplete recovery. 
Other factors common in the poor outcome group were absence of tendon 
reflexes from onset, severe weakness in distal muscles and a relatively low 
CSF protein. However majority of studies have failed to find any correlation 
between CSF protein and outcome. 
 
 In a study by J.B. Winer et al,61 time taken to become bed bound, 
severity of peak deficit, need for assisted ventilation, age greater than 40, and 
small compound muscle action potentials in the abductor pollicis brevis 
elicited by stimulating the median nerve, were found to be associated with 
poor outcome. However, time from onset of weakness until improvement 
began and duration of plateau phase, failed to show a significant correlation 
with outcome. This conclusion conflicts with previous observations56 in which 
failure to improve within 3 weeks of reaching peak deficit adversely affected 
outcome. In yet another study by NK Singh et al,53 rapid progression of illness, 
severe degree of paralysis and muscle wasting, prolonged period of peak 
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paralysis lasting more than weeks, delayed onset of recovery not commencing 
within 3 weeks from onset of weakness, bulbar paralysis and respiratory 
involvement adversely affected outcome. Evidence of axonal damage in 
electrodiagnostic studies was also associated with poor outcome. However 
age, sex, severity of sensory loss, sphincter disturbances, CSF findings and 
nerve conduction velocity did not significantly affect outcome. Autonomic 
dysfunctions were noticed in 66.6% cases but were mostly mild and transient, 
and did not affect longterm outcome. 
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MATERIALS AND METHODS 
 
 All adult patients (> 12 years of age) diagnosed as Guillain Barre 
Syndrome (GBS) fulfilling the criteria as modified by Asbury, admitted in the 
medical wards of Rajiv Gandhi Govt. General Hospital, Chennai-3, from April 
2013 to March 2014 were included in this study. 
 
 A detailed history with particular attention to the date of onset of 
neuropathic signs and the tempo of ensuing functional disability was elicited 
and a clinical examination was performed at admission as per the proforma. 
 
 Repeat examinations of muscle power were performed on alternate days 
till discharge and follow up examination at the end of 3 months. Autonomic 
function tests were performed at admission and repeated at peak disability.  
During each examination, the following were noted: 
 
1. Medical Research Council Grading of muscle weakness. 
2. Disability Grade (0 - 6) was noted according to the following. 
0 - Healthy. 
1  - Minor symptoms or sings. 
2 - Able to walk 5m without assistance, walking frame, or stick but  
unable to do manual work including housework, shopping or 
gardening. 
3 - Able to walk 5m with assistance, walking frame, or stick.  
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4 - Chair/bedbound. 
5 - Requiring assisted ventilation (for at least part of day or night). 
6 - Dead. 
 
3. Bedside Autonomic function tests - Resting Heart rate, Resting Blood 
Pressure, Postural Hypotension, Blood pressure changes at the end of 
one minute and 3 minutes on standing from lying position, wherever 
possible. In addition complaints suggestive of autonomic dysfunction 
such as excessive sweating, urinary retention and constipation, 
palpitations, postural giddiness were also noted. 
 
Criteria for autonomic dysfunction: 
Tachycardia :   Resting heart rate above 100 beats per minute in the absence 
of any secondary cause for increased heart rate such as fever or hypoxia. 
 
Bradycardia: Resting heart rate below 60 beats per minute. 
 
Hypertention: Supine/sitting blood pressure of more than 140/90 mmHg in 
previously nomotensive patients. 
 
Hypotension: - Systolic blood pressure less than 90mmHg. 
 
Postural Hypotension:- Fall in systolic blood pressure by greater than 30 
mmHg on standing from lying position. 
 
37 
 
 Laboratory investigations were performed (as mentioned in the 
proforma) at admission, including hepatitis B serology and HIV serology, 
wherever required, Cerebrospinal fluid examination was done in all the 
patients and Nerve conduction studies were also done in all patients. 
 
 All patients were treated conservatively with physiotherapy and 
mechanical ventilatory assistance, where required. Patients who detoriotated in 
hospital were treated with intravenous Immunoglobulin (0.4g/kg/for 5 days) 
and some patients treated with steroids i.e., intravenous methylprednisolone 
and plasmapheresis depending on availability of drug. Time taken to reach 
peak deficit, interval from maximum deficit to onset of improvement (plateau 
time), duration of ventilatory support required and nature of complications 
were noted. 
 
 For analysis, patients were then divided into two groups; Disability 
grades 0 -3 at the end of 3 months were grouped as 'Good Outcome' whereas 
disability grades 4-6 were taken as 'Bad Outcome'. Frequency of various 
possible prognostic factors within the two groups was then determined and 
possible associations were tested. Statistical methods used to analyze the 
results included Mean + standard error of mean (SEM) value, and Fisher's 
exact probability test (by computer analysis). P values of <0.05 were 
considered significant. 
 
 RESULTS
 A total of 30 patients were studied. All patients were hospitalised and 
the average duration of hospital stay was 17.57 days.
 
1. Age and Sex distribution:
 Twenty-two patients (73.33%) were males and 8(26.67%) were females. 
The age of patients ranged from 13 to 67 years (Mean age 40.87 years) with 
the maximum number (46.67%) of patients in the above 40 age group
(Table-1). 
 
Table 1: Age and sex distribution
 
Sex 12 - 20 
M 3  (10%) 
F - 
Total 3 (10%) 
 
\
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3
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Age 
21-30 31-40 >40 
5 
(16.67%) 
3 
(10%) 
11 
(36.67%)
1 
(3.33%) 
4 
(13.33%) 
3 
(10%) 
6 
(20%) 
7 
(23.33%) 
14 
(46.67%)
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5
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Age & Sex Distribution
  
Total 
 
22 
(73.33%) 
8 
(26.67%) 
 
30 
100%) 
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2. Seasonal incidence :
 
 The least number of cases were seen in the months of April to June.
 
 However no significant 
could be inferred. (Tablc
 
Table 2
 
Months 
Jan - March 
April - June 
July - September 
Oct-December 
 
 
11
39 
 
increased incidence in any particular season 
-2). 
 : Seasonal incidence in GBS 
No. of cases Percentage
7 
5 
7 
11 
7
5
7
Seasonal incidence in GBS
 
 
23.36% 
16.67% 
23.36% 
36.67% 
 
Jan - March
April - June
July - September
Oct-December
 3. Preceding illness: 
 
Twenty (66.67%) patients had some antecedent event prior to the 
development of GBS (Table
upper respiratory tract infection. In patients with a history of 
the mean duration between onset of GBS and the 
(± 4.21) days. 
 
 
Antecedent events
Upper respiratory tract infection
Diarrhoea 
Post vaccination 
Lower Respiratory tract infection
Fever 
None 
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infection
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8
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-3). The most common antecedent illness was 
preceding
Table 3 : Antecedent events 
 No. of patients 
 8 
2 
1 
 2 
7 
10 
Post 
vaccination
Lower 
Respiratory 
tract 
infection
Fever
2
1
2
7
Antecedent events
preceding illness, 
 illness was 9.06  
Percentage (%) 
26.67 
6.67 
3.33 
6.67 
23.33 
33.33 
 
None
10
41 
 
4. First Symptom of illness: 
 
 The first symptom of the illness was in the form of motor weakness in 
11 (36.67%) patients and it was sensory in the form of pain, paraesthesiae or 
numbness in the remaining 19(63.33%) patients. Details are shown in Table-4. 
 
Table 4. First symptom 
 
Motor symptoms No. of patients Percentage 
Weakness of legs 6 20 
Weakness of legs and arms 2 6.67 
Weakness of arms alone 3 10 
Total 11 36.67 
Sensory symptoms No. of patients Percentage 
Paraesthesiac 10 33.33 
Pain in legs 3 10 
Pain in back 2 6.67 
Numbness in legs 2 6.67 
Generalised muscle aches 2 6.67 
Total 19 63.33 
 
 Twenty two (73.33%) patients experienced some sensory symptoms 
during the course of their illness mainly in the form of paraesthesiae in hands 
and feet. Eight (26.67%) patients did not have any sensory symptoms 
throughout the course of their illness. 
  
 5. Mode of onset: 
 
 Twenty two patients (73.33%) had ascending form of paralysis. Only 5 
(16.67%) patients had descending type of paralysis (Table
weakness occurred in the proximal muscles initially and later progressed to the 
distal muscles in 17 patients. Progression from distal to proximal muscles were 
seen in 9 patients, three patie
proximal and distal muscles.
 
Mode
Ascending paralysis 
Descending paralysis 
Simultaneous involvement of all 4 
limbs 
 
 
5
42 
nts had simultaneous involvement of both 
 
Table 5. Mode of onset of GBS 
 No. of patients 
22 
5 
3 
 
22
3
Mode of onset of GBS
Ascending paralysis
Descending paralysis
Simultaneous 
involvement of all 4 
limbs
-5). Muscle 
Percentage 
73.33% 
16.67 
10% 
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6. Maximal grades of disability: 
 
 Twelve patients took upto 1 weak to reach maximal weakness, 15 
patients took upto 2 weeks, 2 patients took upto 3 weeks and 1 patient took 
longer than 3 weeks (24 days). The maximum number of admitted patients 
(40%) reached grade 4 disabilities at peak (Table-6). 
 
 Ten patients (33.33%) developed respiratory paralysis and required 
mechanical ventilation. Four (13.33%) patients died. The cause of death was 
septicaemic shock following aspiration pneumonia in 1 patient and cardiac 
arrest while on mechanical ventilation in other 3 patients. One of the patients, 
who had a cardiac arrest, had severe autonomic dysfunction with fluctuating 
blood pressure and heart rate. 
 
Table 6. Maximal grade of disability (at peak) 
 
Grade Number of patients Percentage 
6 4 13.33% 
5 6 20% 
4 12 40% 
3 5 16.67% 
2 2 6.67% 
1 1 3.33% 
 
  
  
7. Sensory Deficit: 
 
 Objective sensory loss was elicited in only 3(10%) out of the 30 
patients. The sensory deficit was in the form of diminished touch, vibration 
and joint position sense, which occurred in a glove and stocking distribution.
 
8. Cranial Nerve Dysfunction:
 
 Eighteen patients (60%) had cranial nerve dysfunction. (Table
Seventeen patients had facial nerve palsy, among which 15 were bilateral. Six 
patients had involvement of 9
ophthalmoplegia was observed in one patient. This patient also had severe 
ataxia and weakness in the lower limbs. A diagnosis of Miller Fisher variant of 
GBS was made in this patient. H
One patient had left recurrent laryngeal nerve palsy.
0
2
4
6
8
10
12
1
6
4
Maximal grade of disability (at peak)
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th
 and 10th cranial nerves. Total external 
ypoglossal nerve was involved in one patient. 
 
2 3 4 5
5
4
3
2
6
12
5
2
Grade Number of patients
 
 
-7) 
6
1 1
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Table 7. Cranial nerve dysfunction 
 
Cranial Nerve Number of patients Percentage 
VII -Unilateral 2 6.67% 
Bilateral 15 50% 
IX, X 6 20% 
III, IV, VI 1 3.33% 
XI 1 3.33% 
XII  1 3.33% 
 
 
9. Autonomic dysfunction: 
 
 Patients who were in Grade 4 disability or more were not subjected to 
standing blood pressure recordings. Only sitting blood pressures were recorded 
in these patients. In patients who were on ventilator, the spontaneous changes 
in heart rate and blood pressure were noted. 
 
 Autonomic dysfunction was detected in 14 (46.67%) patients Table-9.  
 
  
  
 
Sinus Tachycardia 
Sinus Bradycardia 
Sinus Arrhythmia 
Postural Hypotension
Hypertension 
Fluctuating B.P. 
Excessive sweating 
Sphincter Dysfunction
 
2
5
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Table 8. Autonomic dysfunction 
Number of patients Percentage
2 
1 
2 
 1 
9 
2 
5 
 4 
2
1
2
1
9
4
Autonomic dysfunction
Sinus Tachycardia
Sinus Bradycardia
Sinus Arrhythmia
Postural Hypotension
Hypertension
Fluctuating B.P.
Excessive sweating
Sphincter Dysfunction
 
6.67% 
3.33% 
6.67% 
3.33% 
30% 
6.67 
16.67% 
13.33% 
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10. Cerebrospinal Fluid (CSF) Analysis: 
 
 CSF pressure was normal and CSF was clear in all patients. CSF 
glucose was also normal (approximately half the blood glucose level) in all 
patients. 
 
 CSF protein concentration was raised above 50 mg% in 20 (66.67%) 
patients at one week. Three patients had lymphocytic pleocytosis of 20, 30 and 
50 cells/cumm. None of the remaining patients had CSF pleocytosis. 
 
11. Electrophysiological studies: 
 
 Nerve conduction studies were conducted in all patients. Sixteen 
patients were found to have reduced motor conduction velocities consistent 
with demyelinating neuropathy. Seven patients were found to have decreased 
amplitude of action potentials consistent with axonal pattern of neuropathy. 
Three patients had mixed pattern of neuropathy. The remaining 4 patients had 
normal conduction studies. 
 
Table 9. Nerve conduction studies pattern 
Type Number of patients Percentage 
Demyelinating 16 53.33% 
Axonal 7 23.33% 
Mixed 3 10% 
Normal 4 13.33% 
 
  
12. Complications: 
 
 Complications observed are listed in Tab
 
 
 
Aspiration pneumonia
Septicaemia 
Urinary tract infection
Hypotension 
 
0
2
4
6
8
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14
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Nerve conduction studies pattern
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Aspiration 
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7
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Table 10. Complications 
Number of patients Percentage
 7 
1 
 1 
1 
Axonal Mixed Normal
16
7
3
4
Septicaemia Urinary tract 
infection
Hypotension
1
1
1
Complications
 
 
23.33% 
3.33% 
3.33% 
3.33% 
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13. Treatment: 
 All patients received physiotherapy and the 10 patients who developed 
respiratory failure were put on mechanical ventilation. Two patients received 
intravenous immunoglobulins in addition to conservative therapy. Both of 
them showed good response with arrest of progression of muscular muscle 
weakness by 2 to 3 days. 3 patients received intravenous methylprednisolone. 
Patients with intravenous steroids did not show much benefit over supportive 
treatment. 3 patients received plasmapheresis. Among them 2 patients 
responded well with arrest of progression of muscle weakness and one patient 
expired on ventilator. 
 
14. Mortality: 
 Four patients (13.33%) died in this study. All four patients developed 
respiratory failure and required assisted mechanical ventilation. One patient 
developed aspiration pneumonia and later died due to septicaemia and shock. 
The other 3 patients died while on ventilation due to cardiac arrest. In one of 
these patients, severe autonomic dysfunction was observed. The patient had 
fluctuating blood pressure and sinus tachycardia followed by sinus bradycardia 
unresponsive to atropine. He finally died due to cardiac arrest. The cause of 
cardiac arrest in the other two was unexplained. 
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15. Analysis of prognostic factors: 
 Twenty-five out of 30 patients were analysed for prognostic factors in 
GBS at the end of 3 months. The rest 5 patients were lost to follow up. 
 
 Patients were divided into two groups. A 'Good Outcome' group which 
had a disability grade of 3 or less at the end of 3 months and a 'Poor Outcome' 
group which had a disability grade of greater than 3 at end of 3 months. 
Eighteen (72%) patients were found to have a good outcome while 7 (28%) 
had a poor outcome. 
 
FEATURES OF GOOD AND POOR OUTCOME GROUPS: 
 
Table 11. Features of good and poor outcome groups 
Features Good Outcome Bad Outcome 
Mean time to peak (days) 10.7 (±3.24) 7.29(±2.16) 
Median time to onset of improvement 14 days 22 days 
Median plateau time (days) 4 days 10 days 
Median C.S.F. protein 61 mg% 63 mg% 
 
 Patients were then analysed using Fisher's Exact Probability Test with 
reference to various prognostic factors and their significance determined. 
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PROGNOSTIC NEUROGLOGICAL SIGNS 
 
1. AGE: 
 Patients were grouped into two categories: a) 40 years and below and b) 
above 40 years of age.  
 
 Outcome was then determined in each of these groups and the 
significance of age above 40 years as a poor prognostic sign was determined 
(Table-12). 
 
Table 12. Age in relation to outcome 
 
Age Number of patients 
Good outcome 
number  
(%) 
Bad outcome 
number  
(%) 
p. value 
<=40 15 11 (73.33%) 4 (26.67%) 
0.2151 
>40 10 7 (70%) 3 (30%) 
 
The above table shows that age is not a significant factor in prognosis. 
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2. CRITICAL TIME PERIODS 
Table 13. Critical time periods in relation to outcome  
(at 3 months following) 
 
Critical time period 
Number 
of 
patients 
Good 
outcome 
number (%) 
Bad 
outcome 
number (%) 
p.value 
(Fisher's 
test) 
Onset of peak paralysis     
Upto 1 week 7 3 (42.86%) 4(57.14%) 0.042 
> 1 week 18 15 (83.33%) 3 (16.67%)  
Peak paralysis period     
(Plateau)     
Upto 1 week 17 15 (82.24%) 2(11.76%) 0.0016 
> 1 week 8 3 5 (62.5%)  
Onset of recovery     
Upto 3 weeks 20 16(80%) 4 (0%) 0.113 
> 3 weeks 5 2 (40%) 3 (60%)  
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Outcome was determined with reference to: 
a) Time taken from onset of GBS to peak deficit:- The outcome in patients 
who attained peak paralysis in 1 week was compared with those who attained 
peak paralysis after 1 week. 
 
 Seven patients had peak paralysis within the first week and the 
remaining 18 patients attained peak paralysis only after 1 week. Fifteen 
patients in the delayed peak deficit group and 3 patients in the early peak 
deficit group had a good outcome. Four patients in the former group and 3 
patients in the latter had a poor outcome. 
 
 The difference in outcome between these two groups is statistically 
significant. (p=0.042). 
 
b) Duration of Plateau Phase:- Outcome in patients with a peak paralysis 
period (Plateau phase ) of 1 week or less, was compared with outcome in those 
with a peak paralysis period of more than 1 week. Seventeen patients had a 
peak paralysis period of upto 1 week, while the remaining 8 patients had a 
plateau phase of more than 1 week. Fifteen patients in the former group and 3 
in the latter group, had a good outcome. Only 2 patients in the former group 
had a poor outcome, whereas 5 patients in the latter group had a poor outcome. 
The difference in outcome at 3 months in these two groups is highly 
significant (p = 0.0016). 
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c) Duration from onset of GBS to recovery:- The outcome of patients with 
duration from the onset of GBS to onset of recovery of upto 3 weeks was 
compared with outcome of those who took more than 3 weeks to recover. 
Twenty patients started recovering within 3 weeks of onset while 5 patients 
took longer than 3 weeks. Sixteen patients in the former group and 2 in the 
later group had a good outcome. Four patients in the former and 3 in the later 
group had a poor outcome. The difference in outcome in the two groups is not 
statistically significant. (p=0.002) (Table-14). 
 
Table 14. Need for ventilation 
 
 Number of Good outcome Bad outcome p. value 
 patients number (%) number (%)  
Present 6 1 5 0.002 
Absent 19 17 2  
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4. OTHERS: 
 
 Other possible prognostic factors were analysed similarly as shown in 
the Table-15. 
 
Table 15. Other possible prognostic neurological signs 
 
Neurological sign 
Number of 
patients 
Good outcome 
number (%) 
Bad outcome 
number (%) p. value 
 
Severity of paralysis 
    
Power grade 0 - 1 7 2 (28.6) 5(71.4) 0.002 
Power grade 2 - 4  18 16(88.9) 2(11.1)  
 
Sensory loss (Obj.) 
    
Present 3 3(100) - (0) 0.354 
Absent 22 15(68.1) 7(31.9)  
 
Sphincter dysfunction 
    
Present 4 2(50) 2(50) 0.3065 
Absent 21 16(76.2) 5 (23.8)  
 
Bulbar paralysis 
   0.1937 
Present 6 3(50) 3(50)  
Absent 20 16(80) 4(20)  
 
Autonomic dysfunction 
    
Present 13 8(61.5) 5 (38.5) 0.2231 
Absent 12 10(83.3) 2(16.7)  
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 The outcome at the end of 3 months was correlated with the severity of 
paralysis (MRC grading) at plateau period. Seven patients had the power of 0 - 
1, among whom 2 patients had a good outcome and 5 had a poor outcome. 
Eighteen patients had power of grade 2-4, among whom 16 had good outcome 
and 2 had a poor outcome. On applying Fisher's test, the difference in outcome 
in the two groups is found to significant regarding the severity of paralysis and 
final outcome (p=0.006). 
 
 The presence or absence of objective sensory loss was also compared 
with respect to outcome. All 3 patients who had sensory loss had good 
outcome. Among the remaining 22 patients with no sensory loss, 15 had a 
good outcome and 7 had poor outcome. The difference is not statistically 
significant. 
 
 Among the 4 patients who had sphincter dysfunction, equal number had 
good outcome and poor outcome. In the remaining patients without the 
evidence of sphincter dysfunction, 16 had a good outcome and 5 had a poor 
outcome. No statistical significance is observed in outcome between the two 
groups. 
 
  
57 
 
 In 6 patients with evidence of bulbar paralysis, 3 each had a good 
outcome and poor outcome. In patients without bulbar paralysis, 15 and 4 
patients had a good and poor outcome respectively. The difference however is 
not statistically significant. 
 
 Evidence of autonomic dysfunction was seen in 13 patients and 8 of 
them had a favourable outcome at 3 months. In paticntswithout any autonomic 
dysfunction. 10 out of 12 had a good outcome. The difference is not 
statistically significant. 
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DISCUSSION 
 
 A total of 30 patients were included in this prospective study. The 
maximum number of patients were in above 40 years age group (40%). Kaplan 
ct al16 reviewed 2575 cases and found the peak incidence to be between 50 and 
74 years of age with lesser peak between 15 and 35 years. Similarly Peter C. 
Dowling65 also reported two peaks. In Thakaran et al50 series however, the 
mean age of study group was only 28 years. 
 
 There is a male preponderance in our study which is in conformity with 
the report by Robert M. et al.66 However, Peter C. Dowling's 5 study of 176 
patients showed an equal incidence in males and females. 
 
 No seasonal variation in incidence of GBS could be inferred from this 
study in conformity with the majority of studies in literature66. However a few 
studies have noted a seasonal clustering of cases. Kaur et al67 reported an 
increased incidence in summer and autumn. Peter C. Dowling65 also noted an 
increase in summer. 
 
 Twenty (66.7%) of our patients had a definite antecedent event prior to 
onset of illness. Winer et al61 reported that over half of GBS patients 
experience symptoms of viral respiratory or gastrointestinal infections. Ropper 
et al1 also reported a high incidence of 73%. In contrast a study by Kaur et al67 
showed a lower incidence of 32%. 
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 The interval between prodromal illness and onset of GBS is most 
frequently from 1-3 weeks. Occasionally it is as long as 6 weeks. Kaur ct al67 
reported a mean interval of 9.2 days. In our study there is a mean interval of 
9.06 (± 4.21) days between the prodrome and the onset of GBS. The most 
common antecedent illness was upper respiratory tract infection (26.67%) 
while diarrhoeal illness was seen in only two patients (6.67%). 
 
 Ascending paralysis was noted in 73.32 (22 patients) and descending 
paralysis in 16.67% (5 patients), while 10%(3 patients) had simultaneous 
involvement of all four limbs. According to description by Winer et al61 that 
muscle weakness usually starts in legs and ascends to arms in most cases. A 
metaanalysis of large series by Allan H. Ropper21 showed ascending paralysis 
in 60%, descending paralysis in 20% and involvement of all four limbs 
simultaneously in 20% cases. 
 
 In 63.33%) patients, the first symptom of illness was sensory in the form 
of paraesthesia in hands and feet, numbness or pain whereas motor weakness 
was the first symptom in 36.67% of patients. However Robert et al reported 
first symptom as sensory in 83% and motor in 17% of patients. 
 
 73.33% of patients experienced some sensory symptoms mainly in the 
form of paraesthesia during the course of illness. Allan H. Ropper21 in his 
metaanalysis reported 85% incidence of paraesthesia. In a study by Winer et 
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al61 75% patients had paraesthesia, Robert M, et al described 83% incidence in 
paraesthesia. 
 
 Objective sensory loss occurred in 3 patients (10%) in the form of 
diminished touch, vibration and joint position sense which occurred in glove 
and stocking distribution. This is much lower than the 40% reported by Allan 
H. Ropper21 in his metaanalysis. Winer et al61 noted sensory loss in 52% of his 
patients. 
 
 All patients had involvement of the legs and involvement of limbs was 
symmetric in all cases. None of the patients had involvement of hands alone, 
which is in conformity to the observation of Winer et al61 who said that the 
arms are not affected in isolation. 
 
 One patient also had ataxia and involvement of 3rd, 4th and 6th cranial 
nerves. He was diagnosed to have Miller Fisher Variant of GBS. 
 
 Respiratory failure was present in 33.33% of our patients. Allan 
H.Ropper21 in his meta analysis showed that 10% of patients have respiratory 
failure. Winer et al61 noted a 23% incidence of respiratory failure. The average 
duration of mechanical ventilation in our patients was 16.12 days. 
 
 Twenty two (73.33%) patients reached grade IV or more disability 
(bedridden state). In the study by Winer et al61 only 12% retained the ability to 
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walk throughout the illness and the remaining 88% became bedridden. This is 
in contrast to the report by RDM Hadden et al58 who said 40% patients become 
bedbound. 
 
 Overall, about 50% of patients with GBS reach maximal weakness by 1 
week, 70% by 2 weeks, and 80% by 3 weeks in the course of illness. In this 
study 40% of patients reached peak deficit within 1 week of onset of illness, 
90% by 2 weeks. 
 
 60% of our patients had cranial nerve dysfunction. This is in conformity 
with the 50% incidence reported by Winer et al61 and 60% in Allan H. 
Ropper's21 meta analysis. Kaur et al67 reported an incidence of 41% in her 
study from North India. Facial Nerve was the most commonly involved 
(56.67%) in our series in concordance with most series. IX and X cranial 
nerves were involved in only 20% of patients in contrast to the reported 
incidence of 50% in Allan H. Ropper's meta analysis. 
 
 Autonomic dysfunction is reported to occur in upto 50% of GBS 
patients P. Hacheneeker et al   noted dysfunction in 69% of their patients. NK 
Singh et al63 documented 67% incidence. In this study autonomic dysfunction 
occurred in 46.67% of patients.8 Transient sphineteric dysfunction in the form 
of urinary retention and hesitancy was seen in four (13.33%) patients. Allan 
H.Ropper's meta analysis reported 15% incidence of transient bladder 
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disturbances in GBS patients NK Singh et al63 observed sphincter disturbance 
in 20% of patients. 
 
 CSF protein was raised above 50mg% in 20 patients. Winer et al61 
reported raised CSF protein in 80% patients while 90% was reported in Allan 
H.Ropper's21 meta analysis. The lower number of patients with raised CSF 
protein in this study was probably because all CSF studies were done between 
1 and 2 weeks from onset and not repeated thereafter. It is possible that there 
may have been a rise in CSF protein later in the course of illness, which was 
not recorded. Furthermore, it has been noted in some studies that CSF protein 
may not rise throughout the course of illness in some patients with GBS. Gupta 
RC3 reports such patients did not show rise in CSF protein even at 6 weeks. 
 
 CSF pleocytosis was seen in three patients. CSF mononuclear cell 
counts of upto 50 per emm may be seen in GBS and does not rule out 
diagnosis of GBS. 
 
 Electrophysiological studies were conducted in all patients and 16 of 
them showed demyelinating pattern, 7 of them showed axonal pattern, 3 
patients mixed pattern remaining 4 patients had normal pattern of nerve 
conduction studies and patients having mixed and axonal pattern showed poor 
prognosis compared to patients having demyelinating and normal nerve 
conduction study. 
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 Many authors have found a proportion of patients to have normal nerve 
condution. The population varies form 9% to 20%70 and is higher in the first 
few weeks of illness. This finding has been explained as due to 1) The patchy 
nature of pathology of GBS which means that studies confined to one or two 
nerves may miss abnormal findings. 2) Maximum conduction velocities may 
conceal abnormalities since conduction can occur normally in some fibres 
while being partially blocked in some others. 3) Lastly it is likely that proximal 
conduction blocks occur commonly in GBS that distal motor conduction 
would be unaffected. 
 
 Four patients died in this study. All 4 patients developed respiratory 
failure and required assisted mechanical ventilation. One patient developed 
aspiration pneunomia and later died due to Septicaemia and shock. The other 3 
patients died while on ventilator due to cardiac arrest. 
 
 Case fatality in this study was 13.33%. Mortality in GBS varies from 
1.3% to 13% in different series with a mean of about 6% Winer et al 1 reported 
13% mortality in his study of 100 patients. NK Singh et al63 noted 8% 
mortality. 
 
PROGNOSIS: 
 A number of studies have been conducted in an attempt to correlate 
particular clinical features of GBS with prognosis in order to be able to select 
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only patients with a poor prognosis for a treatment which involves discomfort, 
expense and risk of complications. 
 
 In this study, we analysed 25 patients in relation to outcome at the end 
of 3 months. Patients were divided into 'Good outcome' group and 'Poor 
outcome' group depending on their disability grade at the end of three months. 
A disability grade of 3 or less at the end of three months was taken as good 
outcome while a disability grade of greater than 3 was considered poor 
outcome. Various possible prognostic factors were then analysed statistically 
using Fisher's exact probability test. 
 
 In a study by J.B. Winer et al61 age greater than 40 years was found to 
be a significant prognostic factor. However, in a previous study by same 
author, age had not been found to significantly influence outcome. Similarly 
NK Singh et al63 also found that age did not affect outcome. In our study too, 
age was not found to be a significant prognostic factor. 
 
 A poor prognosis has been observed in some studies, in patients having 
a rapid progression of weakness, a prolonged period of peak paralysis 
(Plateau) and a delayed onset of recovery, not commencing within 3 weeks 
from onset of weakness. Winer et al, in a retrospective study of 71 patients, 
noted that a prolonged plateau time and a failure to improve within 3 weeks 
were associated with poor prognosis. 
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 In another prospective study61, it was found that patients who reached 
peak paralysis rapidly within seven days had a poor prognosis. This study61 
contradicted the previous study56 in that prolonged plateau period and a 
delayed onset of recovery were not found to be significant factors in prognosis. 
The study by NK Singh et al63 found that all three time periods i.e., rapid 
progression to peak paralysis within seven days, prolonged plateau period, and 
a delayed onset of recovery greater than 3 weeks, were significant prognostic 
factors. In this study rapid progression to peak paralysis within seven days and 
prolonged plateau period greater than 7 days were found to be significant 
prognostic factors. However delayed onset of recovery of more than 3 weeks 
was not found to be a significant prognostic factor. 
 
 Mean CSF protein level in both the good outcome and the poor outcome 
groups did not show marked difference indicating that CSF protein 
concentration does not influence the outcome n these patients. This is in 
accord with majority of studies in literature which have failed to find any 
correlation. 
 
 The need for assisted ventilation has also been found to be a significant 
prognostic factor in our study which is in accord with the prognostic studies of 
both NK Singh et al63 and Winer et al.61 
 
 Other possible prognostic factors analysed in this study were severity of 
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muscle weakness at peak, presence of objective sensory loss, sphincter 
disturbance, cranial nerve paralysis and autonomic dysfunction. However, 
none of the above parameters were found to be statistically significant. The 
study by NK Singh et al63 shows similar results with severity of paralysis at 
peak, adversely affecting outcome in the patients. However, his study shows 
that presence of bulbar paralysis is also associated with a poor prognosis. In 
our study, although out of 18 patients with cranial nerve paralysis, four had a 
bad outcome, the association with outcome is not found to be significant. 
 
 In summary, delayed onset of recovery from paralysis, requirement of 
mechanical ventilatory support are significant prognostic factors of outcome in 
GBS. 
 
 The drawbacks of our study were incomplete follow-up of 5 patients due 
to patient drop out. 
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CONCLUSIONS 
 
1. GBS occurs in all age groups with a greater incidence in the older age 
group above 40 years. However age does not have any correlation with 
prognosis. 
2. GBS affects both sexes; however males are affected more than females 
in the ratio of 11:04. 
3. Upto 2/3rds of patients report a definite antecedent event prior to onset 
of GBS. 
4. Onset of GBS is heralded by sensory symptoms in the majority of 
patients. However, objective sensory deficit is seen in very few patients. 
5. Ascending type of paralysis is most commonly seen in GBS with a 
predominant proximal muscle weakness. 
6. Progression to maximal motor deficit occurs within 2 weeks in 90% of 
patients. Progression of muscle weakness beyond 4 weeks is not seen. 
7. Respiratory failure occurs in l/3rd of patients in GBS. 
8. Autonomic dysfunction is very common in GBS. But is has no 
correlation with prognosis. 
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9. Cranial nerve dysfunction occurs in 60% of patients in GBS. Facial 
nerve is most commonly involved. 
10. Albuminocytological dissociation is seen in majority of patients of GBS 
after 1 week. However, CSF protein level has no prognostic value. 
11. Rapid progression from onset to peak paralysis, prolonged duration of 
peak paralysis, need for ventilatory support and severity of paralysis are 
the factors associated with poor prognosis in GBS. 
12. Nerve conduction study results consistent with axonal pattern and mixed 
pattern of neuropathy are associated with poor prognosis. 
13. Mortality in GBS is 13%. 
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